A Study of Thymic Humoral Factor (THF Gamma 2) in HIV-Infected Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To investigate the safety of thymic humoral factor (THF gamma 2), its effect on HIV load
based on at least a 75 percent decrease in HIV quantitative PCR RNA copies/ml, and its
persistence when administered in combination with an antiretroviral nucleoside derivative
(zidovudine; AZT). To assess the effects of THF gamma 2 on T-cells, quality of life, and
progression of disease.